Jennison Associates’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Jennison Associates’s Portfolio BSX.PRA Stock Details BSX.PRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,616	Closed	-$1.16M	–	641
2023 Q1	$1.16M	Hold	9,616	–	–	﹤0.01%	482
2022 Q4	$1.1M	Hold	9,616	–	–	﹤0.01%	476
2022 Q3	$973K	Hold	9,616	–	–	﹤0.01%	512
2022 Q2	$975K	Hold	9,616	–	–	﹤0.01%	524
2022 Q1	$1.12M	Hold	9,616	–	–	﹤0.01%	546
2021 Q4	$1.1M	Buy	+9,616	New	+$1.1M	﹤0.01%	599
2020 Q4	–	Sell	-10,065	Closed	-$1.13M	–	718
2020 Q3	$1.13M	Sell	10,065 -935	-9%	-$105K	﹤0.01%	545
2020 Q2	$1.15M	Buy	+11,000	New	+$1.18M	﹤0.01%	519

Other funds holding BSX.PRA

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Jennison Associates's BSX.PRA Position: Q2 2023 in Review

Jennison Associates sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2023, closing a stake of 9,616 shares — an estimated $1.16M sold.

Jennison Associates first reported a position in BSX.PRA in Q2 2020 and held it in 8 quarters. The position peaked at $1.16M in Q1 2023. 1 fund tracked by Wall St. Rank holds BSX.PRA as of Q2 2023.

Jennison Associates reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2023 after selling out during the quarter.
Jennison Associates sold 9,616 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2023, an estimated $1.16M.
Jennison Associates first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q2 2020 and held it in 8 quarters.
Jennison Associates's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $1.16M in Q1 2023.
1 fund tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2023.

Based on Jennison Associates's 13F filing for Q2 2023, filed 3 Aug 2023.